ME03481B - Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors - Google Patents
Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitorsInfo
- Publication number
- ME03481B ME03481B MEP-2019-147A MEP2019147A ME03481B ME 03481 B ME03481 B ME 03481B ME P2019147 A MEP2019147 A ME P2019147A ME 03481 B ME03481 B ME 03481B
- Authority
- ME
- Montenegro
- Prior art keywords
- parp
- adp
- ribose
- polymerase
- inhibitors
- Prior art date
Links
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 title abstract 3
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 title abstract 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 125000003368 amide group Chemical group 0.000 title 1
- 150000002473 indoazoles Chemical class 0.000 title 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 206010057430 Retinal injury Diseases 0.000 abstract 1
- 206010038997 Retroviral infections Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 241000950638 Symphysodon discus Species 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009758 senescence Effects 0.000 abstract 1
- 230000037380 skin damage Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts, stereoisomers or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory discuses, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage, and as chemo and/or radiosensitizers for cancer treatment.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0700432.8A GB0700432D0 (en) | 2007-01-10 | 2007-01-10 | Therapeutic compounds |
| US92131007P | 2007-04-02 | 2007-04-02 | |
| EP14176452.2A EP2805945B1 (en) | 2007-01-10 | 2008-01-08 | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03481B true ME03481B (en) | 2020-01-20 |
Family
ID=37809722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2019-147A ME03481B (en) | 2007-01-10 | 2008-01-08 | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
Country Status (21)
| Country | Link |
|---|---|
| CN (1) | CN101578279B (en) |
| AT (1) | ATE502933T1 (en) |
| CR (1) | CR10910A (en) |
| DE (1) | DE602008005711D1 (en) |
| DK (2) | DK2109608T3 (en) |
| ES (3) | ES2509115T3 (en) |
| GB (1) | GB0700432D0 (en) |
| HN (1) | HN2009001260A (en) |
| HU (1) | HUE044513T2 (en) |
| LT (1) | LT2805945T (en) |
| LU (1) | LUC00072I2 (en) |
| ME (1) | ME03481B (en) |
| MY (1) | MY147789A (en) |
| NI (1) | NI200900135A (en) |
| NZ (1) | NZ578256A (en) |
| PE (1) | PE20081558A1 (en) |
| PT (3) | PT2109608E (en) |
| SI (2) | SI2336120T1 (en) |
| TW (1) | TWI528961B (en) |
| UA (1) | UA97658C2 (en) |
| ZA (1) | ZA200903898B (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106496187A (en) * | 2016-09-14 | 2017-03-15 | 陕西科技大学 | A kind of synthetic method for preparing PARP inhibitor Niraparib |
| CN106432188A (en) * | 2016-09-17 | 2017-02-22 | 青岛辰达生物科技有限公司 | Preparation method of anti-cancer drug 2-[4-((3S)-3-Piperidinyl) phenyl]-2H-Indazole-7-Formamide |
| CN106432187A (en) * | 2016-09-17 | 2017-02-22 | 青岛云天生物技术有限公司 | Chiral resolution method of 2-[4-(-3-piperidyl)phenyl]-2H-indazole-7-formamide |
| CN106632244A (en) * | 2016-09-30 | 2017-05-10 | 陕西科技大学 | A novel synthetic method for preparing an anticancer medicine Niraparib |
| CN106467513A (en) * | 2016-09-30 | 2017-03-01 | 陕西科技大学 | A kind of synthetic method preparing Niraparib |
| CN108201537A (en) * | 2016-12-16 | 2018-06-26 | 苏州苏融生物医药有限公司 | A kind of Ni Lapani sustained and controlled release medicaments composition and application thereof |
| EP3606523A1 (en) * | 2017-03-27 | 2020-02-12 | Tesaro, Inc. | Niraparib formulations |
| CN109081828B (en) * | 2017-06-14 | 2021-03-26 | 上海时莱生物技术有限公司 | Poly(ADP-ribose) polymerase inhibitor, preparation method and use |
| CN111278433A (en) | 2017-09-26 | 2020-06-12 | 特沙诺有限公司 | Nilaparib formulations |
| CN108084157A (en) * | 2018-02-12 | 2018-05-29 | 安庆奇创药业有限公司 | A kind of synthetic method of Ni Lapani |
| CN108203404A (en) * | 2018-03-02 | 2018-06-26 | 上海博邦医药科技有限公司 | (R) synthetic method of -3- Phenylpiperidines or/and the chiral intermediate of (S) -3- Phenylpiperidines and Ni Lapani |
| US20240016775A1 (en) | 2020-02-24 | 2024-01-18 | Fukang (Shanghai) Health Technology Co., Ltd | Anti-coronavirus application of poly adp ribose polymerase inhibitor |
| CN115611860B (en) * | 2021-07-13 | 2024-06-11 | 上海博璞诺科技发展有限公司 | Method for synthesizing nilaparib |
-
2007
- 2007-01-10 GB GBGB0700432.8A patent/GB0700432D0/en not_active Ceased
-
2008
- 2008-01-08 SI SI200831266T patent/SI2336120T1/en unknown
- 2008-01-08 ME MEP-2019-147A patent/ME03481B/en unknown
- 2008-01-08 DK DK08702101.0T patent/DK2109608T3/en active
- 2008-01-08 CN CN2008800019265A patent/CN101578279B/en active Active
- 2008-01-08 HU HUE14176452 patent/HUE044513T2/en unknown
- 2008-01-08 PT PT08702101T patent/PT2109608E/en unknown
- 2008-01-08 ES ES11157369.7T patent/ES2509115T3/en active Active
- 2008-01-08 ES ES14176452T patent/ES2728199T3/en active Active
- 2008-01-08 TW TW097100730A patent/TWI528961B/en active
- 2008-01-08 AT AT08702101T patent/ATE502933T1/en active
- 2008-01-08 PT PT14176452T patent/PT2805945T/en unknown
- 2008-01-08 ES ES08702101T patent/ES2362214T3/en active Active
- 2008-01-08 NZ NZ578256A patent/NZ578256A/en unknown
- 2008-01-08 DE DE602008005711T patent/DE602008005711D1/en active Active
- 2008-01-08 MY MYPI20092876A patent/MY147789A/en unknown
- 2008-01-08 DK DK11157369.7T patent/DK2336120T3/en active
- 2008-01-08 SI SI200830240T patent/SI2109608T1/en unknown
- 2008-01-08 LT LTEP14176452.2T patent/LT2805945T/en unknown
- 2008-01-08 PT PT111573697T patent/PT2336120E/en unknown
- 2008-01-08 UA UAA200908335A patent/UA97658C2/en unknown
- 2008-01-08 PE PE2008000097A patent/PE20081558A1/en active IP Right Grant
-
2009
- 2009-06-04 ZA ZA200903898A patent/ZA200903898B/en unknown
- 2009-07-02 HN HN2009001260A patent/HN2009001260A/en unknown
- 2009-07-02 NI NI200900135A patent/NI200900135A/en unknown
- 2009-07-02 CR CR10910A patent/CR10910A/en unknown
-
2018
- 2018-05-03 LU LU00072C patent/LUC00072I2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20081558A1 (en) | 2008-10-30 |
| DE602008005711D1 (en) | 2011-05-05 |
| DK2336120T3 (en) | 2014-10-06 |
| HUE044513T2 (en) | 2019-10-28 |
| CN101578279A (en) | 2009-11-11 |
| HN2009001260A (en) | 2012-03-26 |
| PT2805945T (en) | 2019-06-06 |
| SI2336120T1 (en) | 2014-10-30 |
| MY147789A (en) | 2013-01-31 |
| ZA200903898B (en) | 2010-04-28 |
| PT2336120E (en) | 2014-10-01 |
| LT2805945T (en) | 2019-06-25 |
| ES2509115T3 (en) | 2014-10-17 |
| SI2109608T1 (en) | 2011-07-29 |
| ATE502933T1 (en) | 2011-04-15 |
| PT2109608E (en) | 2011-05-30 |
| ES2728199T3 (en) | 2019-10-22 |
| DK2109608T3 (en) | 2011-07-11 |
| UA97658C2 (en) | 2012-03-12 |
| NI200900135A (en) | 2010-08-30 |
| TW200836731A (en) | 2008-09-16 |
| LUC00072I2 (en) | 2018-07-04 |
| ES2362214T3 (en) | 2011-06-29 |
| NZ578256A (en) | 2011-12-22 |
| GB0700432D0 (en) | 2007-02-21 |
| CR10910A (en) | 2010-01-19 |
| TWI528961B (en) | 2016-04-11 |
| CN101578279B (en) | 2013-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009007200A (en) | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors. | |
| ZA200903898B (en) | Amide substituted indazoles as poly (ADP-Ribose)polymerase (PARP) inhibitors | |
| MX2010005070A (en) | Pyridazinone derivatives as parp inhibitors. | |
| WO2007138351A3 (en) | Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp) | |
| WO2008103277A3 (en) | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors | |
| IN2012DN01453A (en) | ||
| ATE543811T1 (en) | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | |
| MX2013001204A (en) | Compounds for the treatment/prevention of ocular inflammatory diseases. | |
| EA201190158A1 (en) | Derivatives of benzofuranyl for use as glucose kinase inhibitors | |
| WO2010045251A3 (en) | Spiro-oxindole compounds and their use as therapeutic agents | |
| MX2012001838A (en) | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation. | |
| EA201070864A1 (en) | NEW HETEROCYCLIC COMPOUNDS | |
| WO2008017883A3 (en) | 4-oxo-4,5-dihydropyrrolo[1,2-a] quinoxaline derivatives as inhibitors of poly(adp-ribose)polymerase(parp) | |
| WO2011147951A8 (en) | Cycloamino derivatives as gpr119 agonists | |
| GB201114389D0 (en) | Novel compounds | |
| EA201001566A1 (en) | NEW CLASS OF SPYROPIPERIDINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| PH12015500418A1 (en) | Pyridine derivative and medicine | |
| MX2014005538A (en) | 1-pyridazinyl-hydroxyimino- 3- phenyl- propanes as gpbar1 agonists. |